CSPC Pharmaceutical Group Limited (FRA:CVG)
Germany flag Germany · Delayed Price · Currency is EUR
0.7276
+0.0076 (1.06%)
At close: May 21, 2025, 10:00 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2018 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 2018 - 2020
Vitamin C
2.12B
Log In
Log In
Log In
Log In
Upgrade
Vitamin C Growth
13.46%
Log In
Log In
Log In
Log In
Upgrade
Antibiotics
1.60B
Log In
Log In
Log In
Log In
Upgrade
Antibiotics Growth
-5.40%
Log In
Log In
Log In
Log In
Upgrade
Functional Food and Others
1.65B
Log In
Log In
Log In
Log In
Upgrade
Functional Food and Others Growth
-19.38%
Log In
Log In
Log In
Log In
Upgrade
Nervous System
8.85B
Log In
Log In
Log In
Log In
Upgrade
Nervous System Growth
-8.53%
Log In
Log In
Log In
Log In
Upgrade
Oncology
3.34B
Log In
Log In
Log In
Log In
Upgrade
Oncology Growth
-47.02%
Log In
Log In
Log In
Log In
Upgrade
Anti-Infectives
3.66B
Log In
Log In
Log In
Log In
Upgrade
Anti-Infectives Growth
-16.04%
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular
1.77B
Log In
Log In
Log In
Log In
Upgrade
Cardiovascular Growth
-31.16%
Log In
Log In
Log In
Log In
Upgrade
Respiratory System
1.06B
Log In
Log In
Log In
Log In
Upgrade
Respiratory System Growth
-30.84%
Log In
Log In
Log In
Log In
Upgrade
Digestion and Metabolism
1.04B
Log In
Log In
Log In
Log In
Upgrade
Digestion and Metabolism Growth
2.89%
Log In
Log In
Log In
Log In
Upgrade
Other Therapeutic Areas
1.23B
Log In
Log In
Log In
Log In
Upgrade
Other Therapeutic Areas Growth
-7.90%
Log In
Log In
Log In
Log In
Upgrade
Licence Fee Income
-
Log In
Log In
Log In
Log In
Upgrade
Licence Fee Income Growth
-
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2018 - 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 2018 - 2020
Finished Drugs Segment Profit
4.34B
Log In
Log In
Log In
Log In
Upgrade
Finished Drugs Segment Profit Growth
-37.73%
Log In
Log In
Log In
Log In
Upgrade
Vitamin C Segment Profit
297.18M
Log In
Log In
Log In
Log In
Upgrade
Vitamin C Segment Profit Growth
-2239.19%
Log In
Log In
Log In
Log In
Upgrade
Antibiotics Segment Profit
284.28M
Log In
Log In
Log In
Log In
Upgrade
Antibiotics Segment Profit Growth
21.54%
Log In
Log In
Log In
Log In
Upgrade
Functional Food and Others Segment Profit
265.59M
Log In
Log In
Log In
Log In
Upgrade
Functional Food and Others Segment Profit Growth
-50.72%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 2017 - 2019
Mainland China
Log In
Log In
Log In
Log In
Upgrade
Mainland China Growth
Log In
Log In
Log In
Log In
Upgrade
Other Asian Regions
Log In
Log In
Log In
Log In
Upgrade
Other Asian Regions Growth
Log In
Log In
Log In
Log In
Upgrade
Americas
Log In
Log In
Log In
Log In
Upgrade
Americas Growth
Log In
Log In
Log In
Log In
Upgrade
Europe
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
Log In
Log In
Log In
Log In
Upgrade
Other Geographies Revenue (Pre-FY2023 Reporting)
Log In
Log In
Log In
Log In
Upgrade
Other Geographies Revenue (Pre-FY2023 Reporting) Growth
Log In
Log In
Log In
Log In
Upgrade
North America
Log In
Log In
Log In
Log In
Upgrade
North America Growth
Log In
Log In
Log In
Log In
Upgrade
Other Geographies
Log In
Log In
Log In
Log In
Upgrade
Other Geographies Growth
Log In
Log In
Log In
Log In
Upgrade